EUCTR2004-002860-43-IT进行中（未招募）不适用
Master protocol for mantle cell lymphomaA multicenter phase II trial testingGemcitabine for the treatment of patients with newlydiagnosed, relapsed or chemotherapy resistantmantle cell lymphomaProtocol SAKK 36/03
SIAK0 个研究点开始时间: 2004年11月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Master protocol for mantle cell lymphoma A multicenter stratified phase II trial testing Everolimus (RAD001) for the treatment of patients with newly diagnosed and relapsed or therapy resistant mantle cell lymphoma - NDmantle cell lymphoma patientsMedDRA version: 9.1Level: LLTClassification code 10061275Term: Mantle cell lymphomaMedDRA version: 9.1Level: LLTClassification code 10026801Term: Mantle cell lymphoma refractoryMedDRA version: 9.1Level: LLTClassification code 10026800Term: Mantle cell lymphoma recurrentEUCTR2007-001108-19-ITSAKK - GRUPPO SVIZZERO DI RICERCA CLINICA SUL CANCRO58
进行中（未招募）
不适用
Master protocol for mantle cell lymphoma. A multicenter phase II trial testing Everolimus ( RAD001) for the treatment of patients with relapsed or thérapy resistant mantle cell lymphoma. Protocol SAKK 36/06Traitement des lymphomes du manteau en deuxième ou troisième ligne (1ère ou 2nd rechute)MedDRA version: 9.1Level: LLTClassification code 10061275Term: Mantle cell lymphomaEUCTR2007-001108-19-FRSAKK35
已完成
1 期
Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell LymphomaMantle Cell LymphomaNCT01484093Memorial Sloan Kettering Cancer Center96
进行中（未招募）
不适用
Traitement de première ligne des lymphomes du manteau de patients agés de 65 à 80 ans. Evaluation de l'efficacité, de la toxicité et de facteurs pronostiques moléculaires de l'inhibiteur du protéasome ( PS341-Velcade) associé à une chimiothérapie et une immunothérapie par rituximab ( schéma RiPAD + C) - MANTEAU 2006 SAEUCTR2006-004768-30-FRGOELAMS
已完成
2 期
Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell LymphomaMantle Cell Lymphoma (MCL)NCT04477486AbbVie13